Drug composite containing calcium 2,5-dihydroxysulfonate and ADP receptor antagonist

A technology of calcium hydroxybenzenesulfonate and receptor antagonists, applied in the field of new pharmaceutical compositions, can solve the problems of reducing patient compliance and rebound of cardiovascular events, and achieve the effect of reducing bleeding rate and inhibiting platelet aggregation

Active Publication Date: 2011-07-27
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If the drug induces an increased risk of bleeding, even if the bleeding is not severe, it will significantly reduce the patient's compliance. The risk of reduced compliance is important in antiplatelet agents, which may lead to rebound cardiovascular events

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composite containing calcium 2,5-dihydroxysulfonate and ADP receptor antagonist
  • Drug composite containing calcium 2,5-dihydroxysulfonate and ADP receptor antagonist
  • Drug composite containing calcium 2,5-dihydroxysulfonate and ADP receptor antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1 common tablet

[0014] Calcium 2,5-dihydroxybenzenesulfonate 200g

[0015] Prasugrel Maleate 2g

[0016] Microcrystalline Cellulose 500g

[0017] Lactose 40g

[0018] 10% starch slurry appropriate amount

[0019] Magnesium stearate 8g

[0020] Preparation process: Weigh the prescribed amount of calcium 2,5-dihydroxybenzenesulfonate, prasugrel maleate, microcrystalline cellulose, and lactose and mix evenly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 2

[0021] Embodiment 2 common tablet

[0022] Calcium 2,5-dihydroxybenzenesulfonate 50g

[0023] Clopidogrel Bisulfate 2.5g

[0024] Starch 140g

[0025] Dextrin 120g

[0026] 50% ethanol appropriate amount

[0027] Magnesium Stearate 1.0g

[0028] Preparation process: Weigh the prescribed amount of calcium 2,5-dihydroxybenzenesulfonate, clopidogrel sulfate, starch, and dextrin and mix evenly. In addition, add an appropriate amount of 50% ethanol to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 3

[0029] Embodiment 3 common tablet

[0030] Calcium 2,5-dihydroxybenzenesulfonate 200g

[0031] Ticlopidine hydrochloride 50g

[0032] Microcrystalline Cellulose 500g

[0033] Lactose 40g

[0034] 10% starch slurry appropriate amount

[0035] Magnesium stearate 8g

[0036] Preparation process: Weigh the prescribed amount of calcium 2,5-dihydroxybenzenesulfonate, ticlopidine hydrochloride, microcrystalline cellulose, and lactose and mix evenly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to a new drug composite, in particular to a drug composite which adopts calcium 2,5-dihydroxysulfonate and ADP receptor antagonist as active ingredients. In order to find a composite drug composite for curing thrombotic diseases which can not only keep the fast and forceful anticoagulation activity, but also effectively reduce the bleeding risk, the inventor finds that usingthe drug composite containing calcium 2,5-dihydroxysulfonate and ADP receptor antagonist which are both used as active ingredients has best synergistic effect and better and faster anticoagulation function through serious and repeated experiments, the bleeding rate is reduced to the minimum and the bleeding risk is greatly decreased so as to increase the overall curative effect and patient compliance for curing thrombotic diseases.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition, in particular to a pharmaceutical composition containing calcium 2,5-dihydroxybenzenesulfonate and an ADP receptor antagonist as active ingredients. Background technique [0002] Calcium 2,5-dihydroxybenzenesulfonate has been clinically used abroad since the 1970s to treat diabetic reticulosis and varicose veins, hemorrhoids, myocardial infarction and itchy dermatitis caused by microcirculation disturbance. Permeability, increase the flexibility of red blood cells, reduce the aggregation of red blood cells, inhibit the number and activity of bradykinin, prostaglandins, platelet activating factor, reduce the level of fibrinogen, inhibit the activation and aggregation of platelets, thereby diluting blood, reducing Whole blood viscosity is currently widely used clinically to treat myocardial infarction, angina pectoris, sequelae of thrombosis, and glomerular arteriosclerosis caused by heart, brain...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/185A61K31/4365A61P7/02
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap